Inhaled Therapy Targets Lung Inflammation After Infection
Inhaled therapies are emerging as a promising approach to manage lingering lung inflammation following respiratory infections, offering targeted treatment directly to the airways with potentially fewer systemic side effects. As respiratory viruses like influenza, SARS-CoV-2, and respiratory syncytial virus (RSV) continue to pose public health challenges, researchers are focusing on post-infectious inflammatory sequelae that can persist for weeks or months, contributing to conditions such as post-viral cough, airway hyperresponsiveness, and even long-term lung dysfunction.
Recent clinical and preclinical studies suggest that delivering anti-inflammatory agents via inhalation may effectively reduce neutrophilic inflammation, mucus hypersecretion, and epithelial damage in the lungs after acute infection. Unlike oral or systemic corticosteroids, which carry risks of immunosuppression, hyperglycemia, and bone loss with prolonged apply, inhaled formulations aim to achieve high local concentrations in the respiratory tract while minimizing exposure to the rest of the body.
One area of active investigation involves inhaled corticosteroids (ICS) in the post-acute phase of COVID-19. While ICS are well-established in managing chronic asthma and chronic obstructive pulmonary disease (COPD), their role after acute viral infection remains under study. A 2023 randomized controlled trial published in The Lancet Respiratory Medicine found that early use of inhaled budesonide in symptomatic outpatients with mild-to-moderate COVID-19 reduced the likelihood of needing urgent care or hospitalization and was associated with faster symptom resolution. Although, evidence for routine use in the post-acute phase (beyond four weeks) is less definitive, and current guidelines from the National Institutes of Health (NIH) do not recommend inhaled or systemic corticosteroids for treating post-acute sequelae of SARS-CoV-2 infection (PASC) outside of clinical trials.
Beyond corticosteroids, novel inhaled biologics and slight molecules are being explored. For example, inhaled formulations of janus kinase (JAK) inhibitors, such as inhaled tofacitinib, are under investigation for their potential to modulate inflammatory signaling pathways locally in the lung. Preclinical models have shown that inhaled JAK inhibition can reduce cytokine-driven inflammation without significant systemic absorption. Similarly, inhaled antagonists targeting the prostaglandin D2 receptor (CRTH2) or thymic stromal lymphopoietin (TSLP) are being studied for their role in modulating type 2 and neutrophilic inflammation seen in post-viral airway disease.
Another strategy involves inhaled antimicrobial peptides or defensins, which may help resolve infection-triggered inflammation by modulating immune cell activity and promoting epithelial repair. Early-phase trials of inhaled LL-37, a human cathelicidin peptide, have demonstrated safety and preliminary signals of reduced sputum neutrophilia in patients with bronchiectasis, a condition often exacerbated by prior respiratory infections.
Delivery technology also plays a critical role in the effectiveness of inhaled therapies. Advances in nebulizer design, soft mist inhalers, and particle engineering have improved lung deposition and allowed for better targeting of distal airways and alveoli—regions often affected in post-infectious lung injury. Proper patient education on inhaler technique remains essential, as suboptimal use can significantly reduce drug delivery to the target site.
not all post-infectious lung symptoms stem from inflammation. Some individuals experience persistent symptoms due to mucus plugging, bronchial hyperreactivity, or even autonomic dysregulation, which may not respond to anti-inflammatory therapy alone. A personalized approach—guided by clinical assessment, spirometry, imaging, and biomarkers when available—is recommended.
As research progresses, inhaled therapies hold potential to become a cornerstone in managing the respiratory aftermath of infection, particularly for individuals at risk of developing chronic airway disease. Ongoing trials are needed to determine optimal agents, dosing regimens, timing, and patient selection criteria. For now, clinicians are advised to rely on evidence-based guidelines and consider inhaled therapies within the context of individualized care, preferably in collaboration with pulmonologists or post-COVID care teams.
Key Takeaways
- Inhaled therapies deliver anti-inflammatory agents directly to the lungs, minimizing systemic exposure.
- Early use of inhaled budesonide may reduce severity in acute COVID-19, but evidence for routine use in post-acute phases is limited.
- Novel inhaled agents, including JAK inhibitors and biologics, are under investigation for targeting post-infectious lung inflammation.
- Proper inhaler technique and appropriate patient selection are critical for treatment effectiveness.
- Not all post-infectious respiratory symptoms are inflammation-driven; evaluation should guide therapy.
- Ongoing clinical trials are needed to define the role of inhaled treatments in post-infectious lung recovery.